Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma
Prostate Cancer
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type

Interventions

BIOLOGICAL: TriAdeno vaccine
DRUG: N-803

Sponsor

National Cancer Institute (NCI)